Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03072550 · ClinicalTrials.gov registry record · NA

Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)

A NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes, sponsored by DeviceFarm.

Completed
Registry status
NA
Development phase
26
Enrollment target
2
Study locations

NCT03072550 is a NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes that has completed, run by DeviceFarm. The registered enrollment target is 26 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03072550, a NA study of Onychomycosis Due to Trichophyton Rubrum and Onychomycosis Due to Trichophyton Mentagrophytes, has completed, sponsored by DeviceFarm.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
2
Study locations

Study Summary

Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.

Interventions

  • DEVICE RenewalNail™ Plasma Treatment System

Study Locations (2)

California

  • Center for Dermatology Clinical Research, Inc. - Fremont
  • Center For Clinical Research Inc. - San Francisco

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2017-03-01
Est. Completion 2018-06-30
Phase NA

Sponsor

DeviceFarm

2 total trials

What the Registry Record Tells You About NCT03072550

The ClinicalTrials.gov registry entry for NCT03072550 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DeviceFarm, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Onychomycosis Due to Trichophyton Rubrum appearing as the primary indexed condition, and to 1 intervention - of which RenewalNail™ Plasma Treatment System is the first listed.

NCT03072550 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03072550 about?

NCT03072550 is a clinical study titled "Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)". Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.

What is the current status of trial NCT03072550?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2017-03-01. Estimated completion is 2018-06-30.

What conditions does trial NCT03072550 study?

This clinical trial studies the following conditions: Onychomycosis Due to Trichophyton Rubrum, Onychomycosis Due to Trichophyton Mentagrophytes.

What interventions are being tested in trial NCT03072550?

The interventions under investigation include: RenewalNail™ Plasma Treatment System (DEVICE).

Who is sponsoring clinical trial NCT03072550?

This trial is sponsored by DeviceFarm, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03072550 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.